Freenome
Valuation each multiple against its own 5-year range
Vs. peers Diagnostics & Research
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Freenome (FRNM) | 1.04B | -3.92 | 2.17 | 0.00% |
| Thermo Fisher Scientific (TMO) | 248.08B | 35.31 | 4.53 | 0.27% |
| Danaher (DHR) | 155.03B | 36.12 | 2.89 | 0.69% |
| IDEXX Laboratories Inc (IDXX) | 53.28B | 45.57 | 28.50 | 0.00% |
| Agilent Technologies (A) | 48.04B | 33.61 | 6.52 | 0.59% |
| Waters (WAT) | 43.29B | 184.29 | 2.83 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 22.0% below Morningstar's fair value estimate.
Fair value
Freenome Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% discount to our quantitative fair value estimate of $11.42 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's valuation metrics increase our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 2.3 falls in the top 20% compared with global peers. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. We believe this is a sign that shares could be undervalued.
On a different note, the company's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, sits in the top 40% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. While we believe the stock is undervalued, this outperformance had a negative impact on our valuation estimate.
Economic moat
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:17 · For reference only, not investment advice and not tailored to your situation.
Freenome discussion 0 comments